Nektar Therapeutics (Nasdaq: NKTR) today presented new data from the ongoing REZOLVE-AD Phase 2b study in a late-breaking ...
TODAY ABOUT ASTHMA. NUMBER ONE, THERE ARE NOT ONE, BUT THREE DIFFERENT KINDS OF ASTHMA. AND RIGHT NOW THERE’S ONLY TREATMENT FOR ONE OF THEM. AND NUMBER THREE, FINDING OUT WHICH KIND OF ASTHMA YOUR ...
BOSTON--(BUSINESS WIRE)--Kinaset Therapeutics, a clinical-stage biopharmaceutical company developing inhaled therapeutics to treat serious respiratory diseases, today announced an upcoming oral ...
ATS 2007, SAN FRANCISCO—Researchers studying inhaled steroids and children with asthma, as well as asthma and obesity, will present new findings from the National Heart, Lung, and Blood Institute ...
Connect Biopharma Holdings Limited announced promising results from its clinical studies of rademikibart, an investigational anti-IL-4Rα antibody, at the EAACI 2025 Annual Congress. The data show that ...
Please provide your email address to receive an email when new articles are posted on . Fewer patients achieved remission with mepolizumab when more stringent definitions including lung function were ...
Connect Biopharma to present data on rademikibart for asthma and COPD at ATS 2025, initiating Phase 2 trials in 2025. Connect Biopharma Holdings Limited announced its plans to present four posters at ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback